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HEAL m REFORM AND ITS IMPLICnONS
Khalib Abdul Latip .& Nik Shamsidah Nik lbrahim .
ABSTRACI'
This paper discusses the various types of health reforms, its objectives and principles. Rl&LYtrations and examples
of health reforms were given namely dnlg financing health reform, reform in maternal and child health services
and health reforms in South Africa, Zambia and Malaysia. Issues in health reforms were also discussed.
INTRODUCI'ION poor value for money (Dekker 1994). Most
attention goes to the supply side, and the refonn
debate is dominated by a focus on
administrative/financial and organizational issues
(Oevretveit 1994). There is a characteristic shift
towards market-derived incentives in pursuit of
micro-economic efficiency and control of
expenditure (Saltman 1994).
Developing countries are increasingly
interested in following similar approaches in order to
control costs, and to correct obvious government
failures in financing and provision of health care
(World Bank 1993). As in Europe, reliance on the
private sector and managed markets is supposed to
enhance provider efficiency through competition and
substitution of direct management with contractual
relationship.
A growing number of developing countries
are now embarking on reforms in which contracting
out clinical services -and specifically hospital care
-is the key element. The speed with which these
approaches have been endorsed in development
circles is in sharp contrast with the lack of actual
experience and empirical evidence for success (Carr-
Hill 1994). Appropriate regulation technologies and
capacities need to be developed. Reforming the
health care sector in developing countries is indeed
subject to specific constraints that center around the
government's regulatory capacity and the strength of
its bargaining position (McPake & Hongoro 1995).
From the above discussion, it is noted that
some of the reasons for health refonn are as
follows:-
.Inability to control cost
.Crisis in financing health sector
.Criticism of bureaucratic rigidity
.Impression of getting poor value for money
.Governments failure to deliver health care
OBJEcrlVES AND PRINCIPLES OF HEALTH
REFORM
What is Health Reform? Health reform means
building on the strength of the current health system
and rcctifying the weaknesses to achieve public
health goodst. Reforms to a better performance of
the health system will ultimately increase the
possibilities of health security and prosperity of a
nation. Health reform is also a complex process and
it requires the courage of the government leadership,
the cooperation and dedicated efforts of the public
and private personnel, and the participation of the
people.
The guiding principles to any health reform
program should consider the following aspects:-
.Universality: covering the whole population
with a basic package of priority services
where everyone in the country has the same
access and benefits ftom the basic health care
provided.
.Quality: improving and ensuring the
standards of care and health facilities,
enhancing diagnoStic and clinical
effectiveness, updating medical education and
training with focus on professionalism, ethical
issues, patient satisfaction and trust with
updated medical technologies.
.Equity: financing for health services is usually
based on ability to pay, while provision of
services is based on needs, thus there should
be an efficient funding scheme which benefits
all members of the community.
.Efficiency: allocation and mobilization of
human, financial and inftastrocture resources
for health based on population needs and
cost-effectiveness.
.Sustainability: ensuring continuity, self
sufficiency and lasting establishment of the
health system reforms and services for the
health and well-being for the present and the
future.
Many European countries have been or are
presently going through a process of reform of the
health care sector. The impetus for such reforms
comes ftom the inability to control costs, criticism of
bureaucratic rigidity, and the impression of getting
Health refonn in its aim to improve the delivery of
health services to the population have the following
objectives and principles.
.Equity; which comprises ensuring access to
essential health services to the portions of the
population at financial and geographical
disadvantage
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f. Working with the private sector (establishing
systems for regulating, contracting with, or
franchising providers in the private sector)
.
TYPES OF HEALTH REFORM AND
EXAMPLES
Quality; which incorporates the effectiveness
of treatment and consumer satisfaction with
health services provided
Efficiency; which includes:-
o Allocative efficiency -distribution of
resources across services so as to
maximize health benefits
o Administrative efficiency -
management structure of health arc
designed to promote most efficiency
use of resources
o Technical efficiency -services are
provided at the lowest possible cost
COMPONENTS OF HEALTH REFORMS
Generally there are two main types of health
reforms:-
.Financing Reform
o Public drug expenditure
0 Health insurance
0 User charge
0 Voluntary and other local financing
0 Donor fmancing and drug donation
0 Development loans
.Organizational reform
0 Primary care strategy
0 Restructuring of services
0 Training of health personnel
Examples of some of the types of health
reforms will be discussed below.
Health reform in drug financing
Using pharmaceutical expenditures as an example,
pham1aceutical expenditures as well as overall
health expenditures, are linked to economic
development (they tend to increase as GDP
increases). However. pham1aceutical consumption
as a percentage of GDP shows much less variation
among regions than does overall health expenditure
(fable 1).
Furthermore, in lower income countries,
pharmaceuticals generally account for a more
significant share of overall health expenditures than
in established market economies (for which this
share is about 15%). For example, in countries such
as China, Indonesia, and Thailand, this share ranges
from 3545% [46]. In several African countries, it is
believed to exceed 50%.
The major components of the health reform involves
the following:-
a. Impraving the performance of civil services
(reducing staff numbers, changing pay,
grading and appraisal system, and reworking
job description).
b. Decentralization (management systems/health
care provision devolved to local government
or other agencies closed to local populations)
c. Improving the functioning of national
ministries of health (organizational
r~cturing to improve human and financial
resources management, monitoring
performance, defIning priorities and cost
effectiveness interventions)
d. Broadening health financing options
(introducing of user fees, community funding
mechanism, s2cial and private insurance
mechanism, voilcher system)
e. Introducing managed competition (promoting
competition between health service
providers/multiple purchasers)
Table I: Health and pharmaceutical expenditures by region, 1990 *
~
Health
expenditures
Region
,
Health expenditures
by source (0/0 of total)
Total % Public Private
per capita GDP
(US$)
Total Private as % of total
.1 pharmaceutical pharmaceutical
expenditures expenditures
Aid Per
capita % GDP
(US$)
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In developing regions, 50 to 90% of the
overall pharmaceutical expenditures are privately
financed, which is considerably higher than in
industrialized countries (median is 34%)
(WHO/DAP 1997).
Because drugs account for such a large
portion of health expenditures, and because the
purchase of these products often requires spending
in foreign currency, inefficiencies in drug
production, procurement, storage, distribution, and
use can be a significant element of waste within the
health sector.
Drug financing reforms, efforts to promote
affordability and efficiency, and organizational
refonns are critical elements in the overall health
sector reform process. Drug financing reforms
involves three main aspects namely financing reform,
affordability and efficiency , and organizational
refohns.
national economic output (GNP), public spending on
health in developing coun1ries is one-quarter to one.
half that of indus1ria1ized coun1ries. Hea!th
fInancing reform should improve the use of public
resources, but it should not be aimed to further
reduce public spending on health.
The level of public commi1ment for financing
health care and drugs should be a matter of explicit
public policy, based on an analysis of health care
needs and fInancing options. Policy makers,
managers responsible for health care fmancing, and
essential drugs managers should be familiar with the
methods for analyzing public financing of drugs and
for planning public expenditures for drugs.
Examples of the public drug financing are
observed in Bhutan and Indonesia as illustrated in
Figure 1.
What determines public spending on health
and drugs? In practice, actual per capita
expenditures are determined by a combination of
factors including: political will; national economic
output (GNP); the share of GNP collected in taxes'as
government revenue; the share of government
spending devoted to health; the existence of publicly
managed health insurance coverage; the share of
health spending devoted to recurrent operating costs
versus capital development costs; and the share of
health spending devoted to pharmaceuticals. Figure
2 illustrates several of these factors for two low-
income countries, one with a high commi1ment o
health and essential drugs spending and one with
low commi1ment.
Drug financing reforms
Health refo111l in drug financing focuses on the
perspective of certain financial aspects of heald1 -
public financing, health insurance, user charges,
donor financing and drug donations, and development
loans.
PubUc financing: Some public spending will
always be needed to ensure access to drugs by the
poorest in society; to ensure proVision of drogs for
tuberculosis, sexually transmitted diseases, and other
communicable diseases; and to ensure care for target
groups such as mothers and children. As a share of
,
Bhutan
.It is unusual for a developing country in that it provides most of its drugs (90%) through
the public sector.
.Public drug expenditure is roughly US$1 per capita annually, 70% of which is covered
directly by the central government allocations (=63% of total phannaceutical spending)
and the remaining 30% is covered by multilateral and bilateral donors.
.An essential drugs list exists (326 dosage forms categorized by levels ofuse in 1995) and
is used in the purehase of drugs through international tenders.
Indonesia
.The public sector contributes one-quarter of the US$ 3.75 per capita whi~h is spent
annually for phannaceuticals by both public and private sources. Of this public
contribution, two-thirds comes from central government allocations (=16.7% of total
phannaceutical spending), with the remaining contributions coming from civil servant
health insurance schemes, provincW and district budgets, and donors .vertical prograIns.
.The central allocation for drugs is deteIn1ined each year on a per capita basis (US$ 0.50
in 1990) using official population figures which set provincial and district budgets.
Districts place their orders for drugs after being notifIed, according to a schedule, of their
budgets, and of prices for drugs on the national essential drugs list. Drugs are delivered to
district warehouses by both public and private supply channels.
Source: WHO/DAP (998). Health reform and drugflnancing: Selected topics
Figure 1 : Role of public drug expenditures in Bhutan and Indonesia
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Figure 2: Public pharmaceutical expenditures in low and high commitment countries
Table 2. Total government expenditures and health expenditures*
Total government Health as % of total Public health
expenditures as e;o GNP government expenditures as e;o
(mediau) expenditures GNP
(median) (mean)
Established market' economies. 42~5 12.5 5.9
Middle Eastern Crescent 33.2 4.3 2.6
Transitionaleconomies 55.6 4.8 3.2
Latin America and Caribbean 17.1 6.7 2.9
Asia and Islands* 19.9 4.7 1.7
Sub-SaharanAfrica 29.7 7.0 1.6
India 17.5 1.6 1.2
China 2.1
expenditures are consistent with regional figures
listed above, but vary greatly among countries. But
within the health sector, the share of budget devoted
to drugs also varies -from 4.5% in Chad and 5.6%
in ThaiJand, to 20.0% in Vie1nam and 36.1% in
Zimbabwe.
The combined effects of lower national
output, government spending as a share of GNP , and
decisions about public spending on health and drugs,
is that per capita drug expenditures Vary greatly
among the 11 countries. Governments in Chad,
Guinea, India (Andhra Pradesh), Ma1i, and Vietnam
all spend less than $0.50 per capita on dru~. Sri
Lanka, a poor country, still manages to spend
US$I.34 on drugs.
Actual regional differences in levels of total
government expenditures and public support for
health are shown in Table 2. In the established
market economies and transitional economies,
central government expenditures total over 40% of
GNP , while the median for government expenditures
in other regions is roughly 20% to 30% of GNP .
Health generally receives less than half the share of
government expenditures in developing countries
(1.6% to 7%) than it does in the established market
economies (12.5%).
How do differences in health and drug
fInancing appear at the national level? Data on total
public health and drug expenditures for 11 countries
are shown in Table 3. Total public health
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Table 3. Public health and drug expenditures for selected countries
Total public health expenditures Total public dru2 expenditures
~ As % GNP Per capita (US$) As % health bud2et Per capita (US$)
Bulgaria 3.9% 44.76 18.4% 8.24
Zimbabwe 2.8% 12.43 36.1% 4.49
Colombia 1.5% 20.03 18.0% 3.61
Thailand 2.0% 33.65 5.6% 1.89
Sri Lanka 1.5% 8.58 15.6% 1.34
Philippines 0.5% 4.53 13.3% 0.60
Vietnam 1.1% 2.32 20.0% 0.46
Guinea 0.4% 1.73 15.8% 0.27
Mali 0.4% 0.74 18.8% 0.14
India (Andhra Pradesh) 3.2% 1.93 6.8% 0.13
Chad 0.6% 1.06 4.5% 0.05
Source: Based on data presented in WHO/DAP. (1996). Informal consultation on evolving public-private roles
in the pharmaceutical sector. Data are from the most recent year available, generally early 1990s.
Not all insurance mechanisms -be they public
or private -will cover the costs of drogs. However,
several arguments can be made for including drugs.
First, drugs are an essential and highly cost-effective
part of modem health care. Second, drugs make up
a large share of household expenses and their
inclusion in either a compulsory or a voluntary
insurance scheme will make the scheme more
acceptable. Finally, effective early treatment of
acute illnesses, such as malaria and pneumonia, and
routine treatment of chronic illnesses, such as
diabetes, not only improves health, but also redu(;es
costly care for complications and hospitalizations.
As illustrated in Figure 3, there are both benefits and
difficulties associated with various insurance
mechanisms.
User charges : User charges are increasingly
being implemented by governments and local
communities in countries at all levels of
development, both to supplement general
government revenues or insurance premiums, and to
help control utilization. Often, however, such
programs have not learned from past experiences,
are not well managed, and, as a result, access shows
no improvement, revenue replaces rather than
supplements government funding, and drugs are
over prescribed.
User fees can complement government
allocations for pharmaceuticals, but should not
replace them. Future efforts need to ensure that the
lessons from existing research and actual experience
are applied to the design, implementation and
monitoring of user fee programs to ensure that
access to drugs does improve and that rational use
does not suffer. When fee mechanistns are instituted
at a national level, a top-down approach, starting
with major national and local hospitals, may have
advantages in terms of equity, reinforcement of the
referral system, revenue potential, administrative
capacity, and impact evaluation.
WHO has previously suggested a minimum
figure of US$ 1.00 per capita annually as an
appropriate target for public expenditures for drugs
(WHO/DAP 1997). However, the adequacy of this
figure depends on several factors, including the
volume of government-fmanced health care, the
range of conditions for which drugs are provided,
and the availability of other financing sources such
as insurance and user fees.
Health insurance : Formal health insurance
and various informal community insurance programs
rq>resent a growing source of health and drug
financing in transitional and developing countries.
The experience of many countries has shown that
compulsory social insurance can be the critical step
to a more equitable health care system. It must be
recognized, however, that some developing
countries will have difficulties in implementing
widespread insurance coverage in the short-term for
a number of reasons including limited formal
employment and weak state mechanisms.
There are benefits in providing
pharmaCeutical coverage together with health
coverage although challenges, such as difficulties in
tracking prescriptions, exist. Policy makers and
managers need to be fully informed about the value
of insurance coverage, alternative mechanisms for
providing pharmaceutical benefits, and methods to
ensure quality of care, while controlling costs.
Universal health insurance is a feature of
almost all the health systems of developed market
economies (a notable exception is the United States
of America) and appears to improve affordability ,
While promoting equity and solidarity in these
systems. In most developing countries, the situation
is quite different. The region with the lowest
insurance coverage (mean) is Sub-Saharan Africa,
10.3%; this is followed by Asia (excluding China
and India), 27.3%; Latin America, 45%; and the
Middle East Crescent, 56.7% (see Table 4).
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Table 4: Distribution of health insurance coverage by region
Population coverage for countries Country distribution of insurance
with insurance coverage
Mean Median Range With Not known or no
insurance insurance#
Regions/countries
Established market economies
Middle Eastern Crescent
Latin America and Caribbean
Asia and Islands*
Sub-Saharan Africa
India
China
98.7
56.7
45.0
27.3
10.3
100.0
50.0
35.5
10.2
8.0
86 -100
15 -100
6- 100
1- 100
1 -26.5
13
7
20
12
14
12
25
13
19
33
5.0
30.0
For the transitional economies, 7 countries have no available data, 11 countries have less than 1%
insurance coverage and the Czech Republic has 100% coverage.
# Coverage is less than 1%
* Except China and India
Source: Creese A L. Kutzin.l: (1995). Lessons from cost-recovery in health. Forum on health sector reform.
Discussion paper No.2. Geneva: World Health Organization
Sodal insurance
Costa Rica: The Costa Rican Social Secwity FWld, CCSS, now provides nearly universal health insurance
coverage to the population. FWlds are derived from a variety of sources including employers, employees, the
self-employed, and a contnoution from the central government CCSS coven; about 800/0 of health
expenditures and includes in this both cw-ative and preventive cafe. Drug availability at CCSS phamJacies is
high and drugs are provided free of charge with no co-payments. They are prescn"bed and dispensed according
to generic name; and are almost always those fOWld in the CCSS fonnulary (535 drogs and dosage
fonns)(MSH/WHO/DAP 1997, Nonnand & Weber 1994)
Thailand: Roughly 72% of the Thai population receives health coverage dJrough some fonn of insunmce.
Both social welfare and social security (providing coverage for 56% of the population) require the use of
essential drogs, while coverage for civil servants and volWltary private insln'ance do not About 67% of health
expenditures are financed privately because patients prefer self-medication and treatment at private clinics,
which public insurance does not cover (WHO/DAP 1996). A separate insurance system -a voluntary health
card scheme -was created to insure those in rural areas for the fees associated with services provided by the
public sector (WHO 1994). Use of essential drugs is mandatory with this public health card [42]. The
effectiveness of this fonn of insurance has yet to be evaluated.
Community-based insurance
Guinea-Bissau: Pre-payment schemes have been developed in rural communities with community-
managed village health posts as a means of ensuring health cafe and drug provision dwing the haJf of the year
in which no monetary economy exists. Villages decide both the rates and the methods of pre-payment Forthose individuals who contnoute, drogs and services are free of charge at the time of provision. Participation is, -
on average, over 9OOfg of those eliglole. Although there were issues ~th drug .-ng due to constraints at
the central medical store, drugs had become more available in two-thirds of the villages and, where this Was not
the case, villagers still perceived the quality of service to have improved (MSH/WHO/DAP 1997, Shaw &
Ainsworthl996)
Private Insurance
Zaire: Although a n~tional insurance mechanism was not determined to be feasible, several mutual
societies in Zaire offer some fonn of health insurance covering both rural and urban areas. Each of these
have different characteristics, and in-depth study of four of them was undertaken to determine their
advantages and disadvantages. The insurance plans studied provided some type of basic or essential drugs
coverage although some plans covered mostly outpatient services while others covered mostly
hospitaliZations. Overall, these local insurance mechanisms resulted in improved access and a more
reliable source offmancing than a system based primarily on user fees (Sanniento 1995)
Figure 3: Financing through health insurance
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In the implementation of user fees, prices are
set through a combination of a market approach
(willingness to pay) and a cost-based accounting
method. There are several types of user charges,
among which are:-
As with donor financing, conditions associated with
development loans should not distort national drug
policies defined by governments.
During the period the period of 1989-1995,
the World Bank contributed a pharmaceutical
lending which amounted to USD 1,311 million.
Countries usually pay from their own resources and
interest set in this funding scheme.
Affordability and effICiency
.Cost of therapy : fIXed fee for an episode of
illness associated with standard treatment
.Prescription: standard fee per drug
.Multi-level item fee: different standard fee for
different drug levels
.Variable item fee: fee differs with drug
depending on type or cost
Most Sub-saharan African countries had some
experience with cost recovery and revolving fund in
the implementation of user charges.
Donor jinIlncing and drug donations :
Donor financing includes bilateral and multilateral
grants. For some countries, internal financing
mec1umiRrn~ for drugs may prove insufficient, even
after reforms, and therefore external funding can
prove invaluable to relieving .immediate human
suffering and can allow countries to develop long-
term solutions.
The challenge with all external financing, but
particularly when it involves the financing of
~t costs, is to not allow this to substitute for
efforts by countries to develop sustainable financing
mechanisms. Transitions from external mech~!1~Rffis
to internal mechanisms need to be incorporated in
assistance plans from their conception. But it should
be recognized that sustainability may require
relatively long-tenn commitments by donors.
Four core principles of dIUg'donation that should be
noted are:-
.Maximum benefit to the recipient
.Respect for wishes and authority of the
recipient
.No double standards in quality
.No effective communication between donor
and recipient
Voluntary and other local fInancing: Non-
governmental organizations are frequently involves
and usually playa significant role. This scheme
usually involve local and external donation. One of
the countries engaging in this scheme is Tanzania
where employer provided health care which are
furnishe.d through contracts with private care
providers or through insurance and reimbursement.
Other then that, that is also a sick fund which will
pay for the cost ofhealth services for the poorest.
Development loans: Development loans
through the World Bank and regional development
banks may contribute to long-term developttlent of
the human and physical infrastructure for the health
sector. However, loans generally should not be used
for financing of the cost of dIUg supplies, as these
represent recurrent expenses. There can exist certain
exceptions to which may justify the use of loans for
procurement (e.g. seeding of revolving drug funds).~
The appropriate choice and use of drugs is the key to
the achievement of phannaceutical policy objectives
and should lead to a greater economic efficiency in
the health sector. A variety of cost-control measures
have been applied at various levels within public and
private drug supply systems. The appropriateness of
different measures varies with particular health
system in each country.
Affordability of drugs for consumers is a
public health concern. Private expenditures for
phannaceuticals in developing countries typically
account for SO to 90% of all spending on drugs.
Even for rural populations and the urban poor, the
moSt common source of drugs is direct out-of-pocket
purchaSe ftom the private market.
Use of generic drugs and price controls are
the two moSt commonly pursued mechanisms to
promote affordability .Generic competition with
price information is effective in this regard. But
generic drug markets have grown very slowly in
most countries. The strength of public policy
commitment to generic drugs is a major detenninant
of the growth of generic markets. Four essential
factors for success appear to be supportive
legislation and regulation, reliable quality assurance,
professional and public acceptance, and economic
incentives.
Various mechanisms exist to control producer
prices and distribution margins. Wholesale and
dispensing margins based on cost plus a flied
professional fee provide a better incentive for
rational dispensing than margins based only on a
percentage. The effects of phannaceutical price
controls have been mixed. Paradoxically, a number
of developing countries are relaxing price controls
on drugs, while governments in industrialized
countries are becoming increasingly concerned with
phannaceutical prices. With or without price
controls, price transparency should be a central
objective.
The main strategies in order to attain
affordability and efficiency are:-
.Therapeutic efficiency in drug selection and
use
.Cost control measures
o Bulk purchasing
o Capping of expenditure\drug selection
o Marketing and advertisement
restrictions
o Prescribing controls or incentives
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.
storage and physical distribution may be integrated
under the essential drugs program, while financing,
quantification of needs, and monitoring may remain
under the management of the national control
program.
Role of the ..'third sector": Public and private
roles in the phannaceutical sector should not ignore
the vital role of the "third sector." This includes
NGOs' health services, not-for-profit essential drugs
supply agencies, professional associations, consumer
groups, and specialized NGOs such as some national
phannacological organizations.
Recently some governments have explored
ways of carrying out "public" functions such as
standard-setting or quality control testing through
innovatiye arrangements with third sector
institutions. Some of the "third sector organizations
that can be involved are service delivery
organizations, consumer o~ni2:~ons, professioiial
associations, standaid-setting organizations and
universities. The various roles played by the third
sector should be clearly acknowledged by policy-
makers, and ways to best support and involve die
sector should be explored.
o Price control
o Promotion of rational use
o Use of generic products
o User fee and co-payments
Affordability for consumers
o Large number of competitors, none of
which possesses a dominant market
share
o Homogeneity of products
o Perfect mobility of resources and low
barrier to entry
o Widespread availability of information
Generic drug strategy
o Supportive legislation and regulation
o Reliable quality assurance capacity
o Professional and public acceptance
o Economic incentives
Organizational reforms
Health reform in maternal and child health
services
Health refonn in the maternal and child health
services involved both financing and organizational
refonns. Among activities involved in this refonn
are immunization, safe motherhood, tax relief for
vaccines, oral rehydration salt (ORS), and
contraceptives supply.
Immunization: Routine immunization
programs are quite cheap per dose of vaccine. The
introduction of vaccine of new vaccines such as
Hepatitis B, Haemophilus influenzae Type B (HiB),
and the new rotavirUs vaccines has also been
delayed in many countries, partly because of their
high costs. The unknown additional costs include:
cold chain, service delivery costs and social
mobilization, (mfonnation, education,
communication).
A survey carried out in 78 countries, indicated
that three quarter of the countri~ have their
immunization programs or vaccine llile items in their
national budgets. Most of the governments pay
personnel costs and are paying more and more of
their vaccine costs, however, few countries pay all
non-personnel costs of their immunization programs
(DeRoeck et al1999, Lieghton 1999). Countries like
Panama, Nicaragua, and Honduras, which pay for all
or nearly all their vaccine costs, still rely on donors
to cover between 16% and 39% of their total
recurrent non-personnel CQsts.
Safe IIWtherhood : Motherhood related
afflictions are the biggest cause of morbidity and
mortality among women between the ages of 15 and
44 (reproductive age group) in developing countries.
Of the 585,000 women who die worldwide from
Refonns to financing systems cannot be made
without organizational refonns that should match the
structure of the public and private sectors to their
responsibilities in fulfilling policy objectives.
Changes may include incorporation of competitive
mechanisms within the public sector,
decentralization of health service provision, and a
.,greater role for nongovernmental organizations
(NGOs) and other non-commercial "third sector"
entities.
Competitive mechanisms in public drug
supply: Alternative drug supply strategies for public
drug supply include the traditional central medical
stores system, autopomous supply agencies, the
direct delivery system, the prime vendor system, and
fully private supply. Several of these systems
involve different public-private roles and rely on
greater competition to improve efficiency.
The practical results of different mechanisms
for public drug supply have yet to be clearly
documented. Governments seeking to improve
efficiency in public drug supply should do so with
the knowledge that a number of options exist and
that success depends not only on choosing an
~propriate option, but also on the way in which the
option is implemented.
Decentralization and integration in drug
supply systems: Control and decision-making in
health systems is increasingly being decentralized.
For drugs, decentralization may improve
quantification of drug requirements, inventory
control, prescn'bing, and dispensing. But some
degree of centralization may still be required for
functions such as drug registration, development of
essential drugs lists and standard treatments, quality
assurance, and bulk tendering.
Efforts are also being made in some countries
to integrate supply syStems for family planning,
tub~rculosis control; and other "vertical" programs
into essential drugs programs. Resource-intensive
functions such as procurement, quality assurance,
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hnpacts of policy change were influenced by
he extent to which financing refonns were linked to
one another. In Zambia for example, there were
weak links between individual resource mobilization
policies: cost sharing policies were implemented
without establishing an effective exemption
mechanism for the indigent, and a mismatch
between prepayment premium leyels and existing
fee levels created perverse incentives for bypassing
primary care facilities. In South Africa, the benefits
of free care policies on utilization and equity were
compromised by slow moving implementation of
policies supporting primary health care. Geograpliic
barriers continued to limit the improvements in
access resulting from the removal of financial
barriers. On the other hand organizational refonns
playa critical role in strengthening capacity to
implement fmancing policy changes and vice versa.
Health reform in Malaysia
In Malaysia, health reform have been one of the on
going continuous process. Various reform activities
have taken place in order to improve equity,
efficiency accessibility and appropriateness of care
namely in the public health sector. Some of the
reform activities include the following:-
complications of pregnancy and childbirth each year,
99% live in developing countries. Another 15
million women have chronic health problems after
childbirth, and 64 million women suffer dangerous
complications from pregnancy. In order to improve
this situation, promotion on increased use of
matemal health services, including safe pregnancy,
care of newborns, women's nutrition, family
planning and other key reproductive health
interventions have been introduced (Lieghton 1999),
This initiative is known as the safe motherhood
initiative.
Activities under this initiative include
gathering information about costs, financing and
effectiveness of maternal health services to help
decision makers design and implement more
efficient and better quality maternal reproductive
health services. The reform agenda are to identify
and remove' financial, management and policy
baniers to effective financing, delivery and use of
maternal and reproductive health services, and
improving clinical knowledge and quality of care.
Focus of activities are removing barriers to
providing and using of services, costing services to
improve value, finding fmancing alternatives and
building local policy capacity (pHR Maternal &
Reproductive Health Initiative 1998)
Tax relief for }laccines ORS and
colltr4cepti}le supplies: A number of developing
countries use tax relief for three public health
commodities -vaccines, oral rehydration salts
(ORS), and contraceptives. Tax relief can take the
form of exemptions, waivers, reductions or some
contnoutions. The ultimate goal of using tax relief is
to improve the health status of population by
increasing the use of public health commodities and
associated services (Lieghton 1999).
A global E..mail survey was carried out in late
1997 to see whether countries granted tax exemption
for these three commodities. Of the 44 countries
queried 22 countries responded: Bolivia, Brazil,
Cambodia, Djibouti, Dominican Republic, Eritrea,
Ghana, Guatemala, Indonesia, Jordan, Kenya,
Madagascar, Malawi, Morocco, Mozambique,
Nicaragua, Philippines, Senegal, Tanzania, Uganda,
Zambia and Zimbabwe. Of the 22 respondents, 15
(68%) grant some form of tax relief (Krasovec &
Connor 1998).
Family Health
o Maternal and Child Health
.Safe Motherhood. This project has lead
to the introduction of alternative
birthing centers at various health
clinics to ensure safe delivery
.Universal child immunization program
.Breast and cervical cancer screening
programs
.Mental and rehabilitation at primary
care level
.Elderly care programs
.Adolescent health care programs etc
0 Primary Care
.Family medicine specialists posted in
health clinics
.Alternative medicines
.New types of facilities providing wider
scope of care and building up of
paperless clinics and hospitals etc
0 Nutrition
.Food basket program for children ag~d
6 years old and below and who are
underweight from hard core poor
families
.Baby Friendly Hospital Initiatives
.Code of ethics of infant formula to
support the breastfeeding initiative
.Micronutrient deficiencies
.Nutrition resource center etc
Health refonn In South Africa and Zambia
In both South Africa and Zambia, health care
financing changes occurred within the broader
programs of health system refom1 that were
intrOduced during the 19908 to improve equity and
efficiency of health care delivery. Table S outlines
the health care financing reforms that were
considered in each country as well as the parallel,
institutional reforms that were implemented (Gilson
et al 2000).
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0 Health insurance etcFood Quality Control
o Food safety
o Food enforcement etc Health Planning and Development
o Upgrading of health care facilities
o Existence of more private health care
facilities
o Upgrading of skills of health personnel
o Review of fees act
o Introduction of specialized services etc
Since its independence, Malaysia have
undergone various levels of reform in order to
improve the health of the nation. More newer
activities are being studied in line with the current
and future requirements.
Disease Control
o Management of emerging of newly infectious
diseases
0 Remerging of old diseases such as
tuberculosis
0 Establishment ofPublic Health laboratory
0 Management of non communicable diseases
etc.
Health Promotion
o Healthy lifestyle campaign
ISSUES
National Health Management Institute
QualIty Programs
o Quality assurance program.
o Quality control
o Quality Control circle
o MS ISO 9000
o Innovations in health
o Health technology assessment etc
There are various issues that need to be looked into
and addressed in making decisions with regards to
health reform. Among the issues are as follows:-
o Balancing the interest of various population,
income, commercial values, and health
provider groups
0 Financial sustainability
o Cost effectiveness allocation of public health
resources and financing alternatives for the
public sector services conflict with or
compromise their traditional equity goals
0 Faces of equity in health sector
Health Financing
o Purchasing of services
o CoIporatization and privatization
Table 5: Reforms of focus in South Africa and Zambia
Type of reforms Spedfic reforms
~ South Africa (1994-1999) Zambia (1991-1999)
Resource Mobilii.ation .Removal of user fees for pregnant. Introduction/expansion of user
and nursing women and children fees
under six and for primary care. .Development of exemption
.Res1IUcturing of public hospital fees policy
.Development of proposals for social .Introduction of prepayment
health insurance scheme
Resource allocation. Development and implemehtation of. Development and
inter-provincial resource allocation implementation of inter-district
formulae resources allocation formulae
.Budget reform to reallocate resources. Budgetary decentralization to
between levels of care district and hospital boards
.Budget reform throughout
government leading to global
budget for provinces.
Parallel, Institutional. Creation of provinces within a semi- .Creation of the Central Board of
reforms federal state Health (CBOH) as
.Proposals to strengthen public implementation arm of the
hospital management Ministry of Health.
.Development of district health .Increased autonomy to public
system referral hospitals and the
establishment of hospital boards
.Strengthening ofdte district
health system with formal
autonomous boards
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CONCLUSION
There are various options c that can be chosen to
improve health services delivery .One must bear in
mind that one need to sacrifice something in order to
obtain another. It is important to be able to balance
the necessity and actual requirements, and get the
optimum benefit from any health reform activities
carried out.
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